Cargando…

Understanding the Potential of Genome Editing in Parkinson’s Disease

CRISPR is a simple and cost-efficient gene-editing technique that has become increasingly popular over the last decades. Various CRISPR/Cas-based applications have been developed to introduce changes in the genome and alter gene expression in diverse systems and tissues. These novel gene-editing tec...

Descripción completa

Detalles Bibliográficos
Autores principales: Arango, David, Bittar, Amaury, Esmeral, Natalia P., Ocasión, Camila, Muñoz-Camargo, Carolina, Cruz, Juan C., Reyes, Luis H., Bloch, Natasha I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430539/
https://www.ncbi.nlm.nih.gov/pubmed/34502143
http://dx.doi.org/10.3390/ijms22179241
_version_ 1783750727013761024
author Arango, David
Bittar, Amaury
Esmeral, Natalia P.
Ocasión, Camila
Muñoz-Camargo, Carolina
Cruz, Juan C.
Reyes, Luis H.
Bloch, Natasha I.
author_facet Arango, David
Bittar, Amaury
Esmeral, Natalia P.
Ocasión, Camila
Muñoz-Camargo, Carolina
Cruz, Juan C.
Reyes, Luis H.
Bloch, Natasha I.
author_sort Arango, David
collection PubMed
description CRISPR is a simple and cost-efficient gene-editing technique that has become increasingly popular over the last decades. Various CRISPR/Cas-based applications have been developed to introduce changes in the genome and alter gene expression in diverse systems and tissues. These novel gene-editing techniques are particularly promising for investigating and treating neurodegenerative diseases, including Parkinson’s disease, for which we currently lack efficient disease-modifying treatment options. Gene therapy could thus provide treatment alternatives, revolutionizing our ability to treat this disease. Here, we review our current knowledge on the genetic basis of Parkinson’s disease to highlight the main biological pathways that become disrupted in Parkinson’s disease and their potential as gene therapy targets. Next, we perform a comprehensive review of novel delivery vehicles available for gene-editing applications, critical for their successful application in both innovative research and potential therapies. Finally, we review the latest developments in CRISPR-based applications and gene therapies to understand and treat Parkinson’s disease. We carefully examine their advantages and shortcomings for diverse gene-editing applications in the brain, highlighting promising avenues for future research.
format Online
Article
Text
id pubmed-8430539
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84305392021-09-11 Understanding the Potential of Genome Editing in Parkinson’s Disease Arango, David Bittar, Amaury Esmeral, Natalia P. Ocasión, Camila Muñoz-Camargo, Carolina Cruz, Juan C. Reyes, Luis H. Bloch, Natasha I. Int J Mol Sci Review CRISPR is a simple and cost-efficient gene-editing technique that has become increasingly popular over the last decades. Various CRISPR/Cas-based applications have been developed to introduce changes in the genome and alter gene expression in diverse systems and tissues. These novel gene-editing techniques are particularly promising for investigating and treating neurodegenerative diseases, including Parkinson’s disease, for which we currently lack efficient disease-modifying treatment options. Gene therapy could thus provide treatment alternatives, revolutionizing our ability to treat this disease. Here, we review our current knowledge on the genetic basis of Parkinson’s disease to highlight the main biological pathways that become disrupted in Parkinson’s disease and their potential as gene therapy targets. Next, we perform a comprehensive review of novel delivery vehicles available for gene-editing applications, critical for their successful application in both innovative research and potential therapies. Finally, we review the latest developments in CRISPR-based applications and gene therapies to understand and treat Parkinson’s disease. We carefully examine their advantages and shortcomings for diverse gene-editing applications in the brain, highlighting promising avenues for future research. MDPI 2021-08-26 /pmc/articles/PMC8430539/ /pubmed/34502143 http://dx.doi.org/10.3390/ijms22179241 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Arango, David
Bittar, Amaury
Esmeral, Natalia P.
Ocasión, Camila
Muñoz-Camargo, Carolina
Cruz, Juan C.
Reyes, Luis H.
Bloch, Natasha I.
Understanding the Potential of Genome Editing in Parkinson’s Disease
title Understanding the Potential of Genome Editing in Parkinson’s Disease
title_full Understanding the Potential of Genome Editing in Parkinson’s Disease
title_fullStr Understanding the Potential of Genome Editing in Parkinson’s Disease
title_full_unstemmed Understanding the Potential of Genome Editing in Parkinson’s Disease
title_short Understanding the Potential of Genome Editing in Parkinson’s Disease
title_sort understanding the potential of genome editing in parkinson’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430539/
https://www.ncbi.nlm.nih.gov/pubmed/34502143
http://dx.doi.org/10.3390/ijms22179241
work_keys_str_mv AT arangodavid understandingthepotentialofgenomeeditinginparkinsonsdisease
AT bittaramaury understandingthepotentialofgenomeeditinginparkinsonsdisease
AT esmeralnataliap understandingthepotentialofgenomeeditinginparkinsonsdisease
AT ocasioncamila understandingthepotentialofgenomeeditinginparkinsonsdisease
AT munozcamargocarolina understandingthepotentialofgenomeeditinginparkinsonsdisease
AT cruzjuanc understandingthepotentialofgenomeeditinginparkinsonsdisease
AT reyesluish understandingthepotentialofgenomeeditinginparkinsonsdisease
AT blochnatashai understandingthepotentialofgenomeeditinginparkinsonsdisease